Comparative Pharmacology
Head-to-head clinical analysis: MYDRIAFAIR versus PAREMYD.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MYDRIAFAIR versus PAREMYD.
MYDRIAFAIR vs PAREMYD
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Antimuscarinic; blocks acetylcholine at muscarinic receptors in iris sphincter and ciliary muscle, causing mydriasis and cycloplegia.
PAREMYD is a direct-acting vasodilator; its active metabolite, hydralazine, relaxes arteriolar smooth muscle by increasing cyclic guanosine monophosphate (cGMP) levels via inhibition of inositol trisphosphate (IP3) production, leading to reduced intracellular calcium and vasodilation.
Administered as one drop of phenylephrine 2.5% and tropicamide 1% ophthalmic solution in each eye 15-20 minutes prior to examination; may repeat once in 5-10 minutes if needed.
10 mg orally twice daily; maximum daily dose: 20 mg.
None Documented
None Documented
Terminal elimination half-life is 1.5 hours; prolonged to 3-4 hours in renal impairment.
Terminal elimination half-life is 12-18 hours; prolonged in renal impairment (up to 40 hours) necessitating dose adjustment.
Renal: 80% as unchanged drug and metabolites; fecal: 20% via biliary excretion.
Primarily renal excretion of unchanged drug (60-80%) and hepatic metabolism (20-40%) with biliary-fecal elimination of metabolites.
Category C
Category C
Mydriatic
Mydriatic